Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia

International Journal of Clinical Practice

Volumn 58, Issue 9, 2004, Pages 859-866

  Gylling, Helena ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiovascular diseases; Cholesterol absorption; Cholesterol synthesis; Therapy

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; RESIN; RETINOID X RECEPTOR; SCAVENGER RECEPTOR; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID ABSORPTION; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ABSORPTION; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 7744236073     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00351.x     Document Type: Review

References (52)

1. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second joint task force of European and other societies on coronary prevention. J Hypertens 1998; 16: 1407-14.
2. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association, 2000.
3. Karnik R. The value of lipid lowering in patients with coronary heart disease. J Clin Basic Cardiol 2001; 4: 31-4.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
6. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001-9.
7. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 1301-7.
8. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
9. Collins R, Armitage J, Parish S et al. for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
10. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
11. Vos J, De Feyter PJ, Simoons ML et al. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis 1993; 35: 435-54.
12. Euroaspire I, II.Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European action on secondary prevention by intervention to reduce events. Lancet 2001; 357: 995-1001.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-421.
14. Schrott HG, Bittner V, Vittinghoff E et al. for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). JAMA 1997; 277: 1281-6.
15. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000; 74(Suppl. 1): S23-S28.
16. Dietschy JM. Theoretical considerations of what regulates low-density lipoprotein and high-density lipoprorein cholesterol. Am J Clin Nutr 1997; 65(Suppl.): 1581S-1589S.
17. Beisiegel U. Lipoprotein metabolism. Eur Heart J 1998; 19(Suppl. A): A20-A23.
18. Brewer HB Jr. Lipid and lipoprotein metabolism. In: Rifkind BM, ed. Drug Treatment of Hyperlipidemia. New York, NY: Marcel Dekker, Inc., 1991.
19. Havel RJ. Origin, metabolic fate, and metabolic function of plasma lipoproteins. In: Steinberg D, Olefsky JM, eds. Hypercholesterolemia and Atherosclerosis: Pathogenesis and Prevention. New York, NY: Churchill Livingstone, 1987.
20. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
21. Millatt LJ, Bocher V, Fruchart J, Staels B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim Biophys Acta 2003; 1631: 107-18.
22. Chen HC. Molecular mechanisms of sterol absorptions. J Nutr 2001; 131: 2603-5.
23. Homan R, Krause BR. Established and emerging strategies for inhibition of cholesterol absorption. Curr Pharm Des 1997; 3: 29-44.
24. Lu K, Lee M, Patel SB. Dietary cholesterol absorption; more than just bile. Trends Endocrinol Metab 2001; 12: 314-20.
25. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999; 40: 302-8.
26. Chiang JYL. Regulation of bile acid synthesis. Front Biosci 1998; 3: 176-93.
27. Phan CT, Tso P. Intestinal lipid absorption and transport. Front Biosci 2001; 6: 299-319.
28. Sehayek E, Ono JG, Shefer S et al. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci USA 1998; 95: 10194-9.
29. Ostlund RE. Cholesterol absorption. Curr Opin Gastroenterol 2002; 18: 254-8.
30. Hernandez M, Montenegro J, Steiner M et al. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter. Biochim Biophys Acta 2000; 1486: 232-42.
31. Hansen GH, Niels-Christiansen LL, Immerdal L, Danielsen EM. Scavenger receptor class B type I (SR-BI) in pig enterocytes: trafficking from the brush border to lipid droplets during fat absorption. Gut 2003; 52: 1424-31.
32. Altmann SW, Davis Hr Jr, Zhu L-J et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
33. Clearfield MB. A novel therapeutic approach to dyslipidemia. JAOA 2003; 103(Suppl. 1): S16-S20.
34. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68: 523-58.
35. Shepherd J. The role of the exogenous pathway in hypercholesterolemia. Eur Heart J Suppl 2001; 3(Suppl. E): E2-E5.
36. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Finnish Treat-to-Target Study Investigators. J Lab Clin Med 2003; 141: 131-7.
37. Watts GF, Chan DC, Barrett PHR, O'Neill FH, Thompson GR. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes 2003; 27: 862-5.
38. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest 2003; 33: 976-82.
39. Ntanios FY, Jones PJ, Frohlich JJ. Effect of 3-hydroxy-3-methylglutaryl coenzyme, a reductase inhibitor on sterol absorption in hypercholesterolemic subjects. Metabolism 1999; 48 68-73.
40. Tsuruoka H, Khovidhunkit W, Brown BE, Fluhr JW, Elias PM, Feingold KR. Scavenger receptor class B type I is expressed in cultured keratinocytes and epidermis. Regulation in response to changes in cholesterol homeostasis and barrier requirements. J Biol Chem 2002; 277: 2916-22.
41. Kosters A, Frijters RJ, Schaap FG et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003; 38: 710-6.
42. Nguyen LB, Shefer S, Salen G, Tint GS, Ruiz F, Bullock J. Mechanisms for cholesterol homeostasis in rat jejunal mucosa: effects of cholesterol, sitosterol, and lovastatin. J Lipid Res 2001; 42 195-200.
43. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
44. Stange EF, Alavi M, Schneider A, Ditschuneit H, Poley JR. Influence of dietary cholesterol, saturated and unsaturated lipid on 3-hydroxy-3-methylglutaryl CoA reductase activity in rabbit intestine and liver. J Lipid Res 1981; 22: 47-56.
45. Chambers CM, Ness GC. Dietary cholesterol regulates hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in rats primarily at the level of translation. Arch Biochem Biophys 1998; 354: 317-22.
46. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
47. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001; 21: 818-27.
48. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. BMJ 1998; 316: 1127-30.
49. O'Neill FH, Patel DD, Knight BL et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001; 21: 832-7.
50. Miettinen TA, Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis 2002; 164: 147-52.
51. Wong ND, Pio JR. Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 1421-6.
52. Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. Rev Cardiovasc Med 2003; 4: 136-41.